Clinical trials: NSCLC (Advanced Non-small Cell Lung Cancer), open to volunteers
Advanced ALK/ROS1-positive NSCLC, Carcinoma, Non-Small-Cell Lung (NSCLC)
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients…
- Conditions
- Advanced ALK/ROS1-positive NSCLC, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Adenocarcinoma, ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07633626
- Where
- Colombia
- Volunteers
- 24 people
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Solid Advanced Tumor, Lymphoma
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.
- Conditions
- Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT05751798
- Testing
- Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 41 people
- Sponsor
- OSE Immunotherapeutics
NSCLC (Advanced Non-small Cell Lung Cancer)
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
This prospective, single-arm, exploratory multicenter clinical study aims to investigate the safety and efficacy of Becotatug vedotin combined with Pucotenlimab (with or without radiotherapy), followed by Pucotenlimab maintenance…
- Trial name
- PRAD2 (NCT07627321)
- Testing
- Pucotenlimab, Becotatug vedotin, Radiotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Anhui Provincial Cancer Hospital
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT06040541
- Testing
- RMC-9805, RMC-6236
- Where
- 17 sites in United States
- Volunteers
- 604 people
- Sponsor
- Revolution Medicines, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Non-Small Cell Lung Cancer, NSCLC
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS<50% NSCLC patients who receive reduced dose chemotherapy in combination with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06731413
- Testing
- Reduced Dose of Chemotherapy and Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
- Conditions
- Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07223047
- Testing
- BMS-986523, Gemcitabine, Nab-Paclitaxel
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 252 people
- Sponsor
- Bristol-Myers Squibb
NSCLC (Advanced Non-small Cell Lung Cancer)
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
- Trial name
- NCT07609251
- Testing
- SCTB41, docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
This study is an open, multicenter, phase II clinical study for evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ALK202 for injection combined with different drugs in participants with locally…
- Trial name
- NCT07603791
- Testing
- ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection
- Volunteers
- 252 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Non Small Cell Lung Cancer (NSCLC)
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC
Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer often diagnosed at advanced stages, with limited treatment options and poor prognosis.
- Trial name
- ALA /NSCLC (NCT07574684)
- Testing
- Alpha Lipoic Acid 600mg
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
NSCLC (Advanced Non-small Cell Lung Cancer)
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
This is a randomized, controlled, multicenter clinical study that enrolled patients with unresectable bulky stage III NSCLC, with PFS as the primary endpoint.
- Trial name
- NCT07560358
- Testing
- After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NSCLC (Advanced Non-small Cell Lung Cancer)
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
This study is a multicenter, open-label, randomized clinical trial aimed at exploring the efficacy and safety of three treatment regimens for treatment-naive advanced NSCLC patients with KRAS G12D mutation: GFH375 monotherapy…
- Trial name
- NCT07554859
- Testing
- ArmA:GFH375, Arm B:GFH375, Arm C:GFH375
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is a prospective, single arm phase II clinical trial aimed at patients with advanced non-small cell lung cancer resistant to EGFR-TKI.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
- Trial name
- PROTECT-2 (NCT06992739)
- Testing
- Trilaciclib and Sacituzumab Tirumotecan
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
The purpose of this clinical trial is to evaluate progression-free survival (PFS) of microwave ablation in combination with tislelizumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have…
- Trial name
- NCT07528274
- Testing
- Tislelizumab, Docetaxel, Microwave ablation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
The goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small…
- Trial name
- IMMUNOLIFE2 (NCT07001618)
- Testing
- MaaT033 capsule, Cemiplimab, Cisplatin
- Where
- 6 sites in France
- Volunteers
- 162 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
The goal of this clinical trial is to clarify the efficacy and safety of the high-dose alternate-day furmonertinib in NSCLC with leptomeningeal metastasis.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
- Trial name
- NCT07348965
- Testing
- Furmonertinib 320mg qod po, Furmonertinib 160mg qd po
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Real-World Study Based on RATIONALE-307
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in…
- Trial name
- NCT07478809
- Testing
- No intervention
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences